Article
CRISPR Gene Editing Delivers Promise for Sickle-Cell Disease, Beta Thalassemia
Rating:
0.0
Views:
117
Likes:
1
Library:
1
CRISPR Therapeutics and Vertex Pharmaceuticals have reported a consistent and sustained positive response in ten patients treated for a pair of blood disorders—sickle-cell disease (SCD) and beta thalassemia—with their CRISPR-Cas9 gene-edited therapy CTX001 in a pair of Phase I/II trials. These are the first clinical studies of a CRISPR gene-editing candidate sponsored by U.S. companies.
Rate This Post
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value